Abstract Background Mineralocorticoid receptor antagonists (MRAs) reduce the risk of
cardiovascular death or heart failure admission in patients with myocardial infarction (MI) …

Aim It is unknown whether safety and clinical endpoints by use of sacubitril/valsartan (an
angiotensin receptor–neprilysin inhibitor [ARNI]) are affected by mineralocorticoid receptor …

The mineralocorticoid receptor antagonist (MRA) eplerenone has been shown to improve
the prognosis of patients who had a myocardial infarction (MI) complicated with symptomatic …

Importance Consensus guidelines recommend the use of mineralocorticoid receptor
antagonists (MRAs) for selected patients with symptomatic heart failure and reduced …

Background There are no studies of mineralocorticoid receptor antagonist (MRA) treatment
examining outcome in unselected real‐life patients with myocardial infarction (MI) and heart …

Aims We investigated the incremental advantage in terms of N-terminal pro-B-type
natriuretic peptide (NT-proBNP) reduction in patients affected by heart failure with reduced …

Despite improvements in the invasive and pharmacological management of myocardial
infarction (MI), patients remain at risk of adverse cardiovascular outcomes in the months and …

Background Sudden cardiac death (SCD) is an important cause of death in patients with left-
ventricular systolic dysfunction (LVSD). Mineralocorticoid receptor antagonists (MRAs) may …

Background Following the EPHESUS trial in 2003, mineralocorticoid receptor antagonist
(MRA) therapy received a class I indication for the management of eligible high-risk post-MI …

Background: There is heated debate about the benefits of using mineralocorticoid receptor
antagonists (MRAs) in addition to standard therapy in patients admitted for myocardial …